Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
Thématique(s) / pathologie(s)
- Maladie de Parkinson
Objectifs
Plus d'informations disponibles sur : https://clinicaltrials.gov/ct2/show/record/NCT02847650?term=2016-001575-71&rank=1
Promoteur
Pfizer
Publication(s) scientifique(s)
-
Riesenberg R et al. PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord. 2020 Mar 6;13.
Statut
Etude arrêtée prématurément
